Welcome to our dedicated page for Therapeutic Solutions Intl news (Ticker: TSOI), a resource for investors and traders seeking the latest updates and insights on Therapeutic Solutions Intl stock.
Therapeutic Solutions International, Inc. (TSOI) generates a steady flow of news centered on immune modulation, stem cell therapy, immunotherapy, and nutraceutical development. This news page aggregates company announcements so readers can follow how its clinical-stage programs, patents, and subsidiaries evolve over time.
Recent press releases highlight progress with the company’s JadiCell universal donor stem cell product in areas such as lung inflammation, COVID-19–related conditions, ARDS, epilepsy, and ALS. News items also cover mechanistic discoveries about how JadiCells interact with immune cells, as well as data suggesting that these cells may enhance gene therapy–mediated production of therapeutic cells.
Another major stream of updates involves the nutraceutical QuadraMune. The company has announced multiple patents related to QuadraMune’s effects on immune pathways, including natural killer cell activity, viral inhibition, brain protection, and modulation of regulatory T cells. These developments are reflected in patent-related news and scientific commentary from company representatives.
Therapeutic Solutions International also issues news about its subsidiaries and pre–spin-off entities, such as Campbell Neurosciences in suicide prevention, Res Nova Bio in oncology immunotherapy, Epilepsy Bio in epilepsy, and ALS Biologics in ALS. Announcements may describe clinical observations under Right To Try, plans for public listings, loyalty dividends of subsidiary shares, and strategic positioning of intellectual property.
In addition, the company has released statements on legal actions and corporate decisions, including its plan to voluntarily delist and "go dark" from the public markets. Investors and observers can use this news feed to review historical announcements on clinical progress, patents, subsidiary formation, legal matters, and capital markets strategy related to TSOI.
Therapeutic Solutions International (TSOI) reported encouraging preliminary results from a collaboration with the Veltmeyer Institute for Advanced Therapeutics. The trial focused on patients with neurodegenerative diseases like ALS and autism. One patient showed a significant increase in T-regulatory cells, rising from 47% to 77% after treatment. Another young patient diagnosed with autism began speaking for the first time following therapy. The company aims to make stem cell treatments accessible and emphasizes its commitment to following FDA regulations.
Therapeutic Solutions International (TSOI) announced the issuance of United States Patent #11,504,410, covering a method to protect and regenerate neurological tissue using various nutraceuticals, including pterostilbene and Nigella sativa. This patent fortifies the company's position in the nutraceutical market and enhances the scientific backing of its product QuadraMune®. The company also noted independent confirmations of the effectiveness of QuadraMune® components, including a study by Johns Hopkins University demonstrating COVID-19 virus inhibition. This is TSOI's third patent linked to QuadraMune®, strengthening its innovation status.
Breathe Biologics, a subsidiary of TSOI, has announced promising data regarding a novel cellular therapy targeting Chronic Obstructive Pulmonary Disease (COPD). Research indicates that monocytic progenitors from umbilical cord blood can reduce inflammation and enhance lung function in animal models. The therapy’s efficacy was linked to the blockade of certain cytokines, suggesting a potential mechanism of action. Breathe Biologics plans to utilize JadiCells, currently in Phase III for COVID ARDS, for COPD treatment under IND# 28508. The collaboration highlights the innovation environment in the USA.
Therapeutic Solutions International (TSOI) has announced the launch of a spin-off company, Breathe Biologics, Inc., aimed at commercializing technologies for COPD. TSOI has licensed its assets, including an Investigational New Drug Application (IND) from the FDA, now known as “Allogeneic Umbilical Cord Mesenchymal Stem Cells, JadiCell.” This innovative stem cell therapy showcases potential in treating COPD and was highlighted by Dr. James Veltmeyer as having remarkable effects on inflammatory diseases. The company's president, Timothy Dixon, is optimistic about rapid commercialization and its positive impact on patients.
Therapeutic Solutions International (TSOI) announced a collaboration between its breast cancer spin-off, Res Nova Bio, and Veltmeyer MD Inc. to provide access to the anti-angiogenic immunotherapy ValloVax for patients with no treatment options. ValloVax has received FDA Investigational New Drug clearance and has demonstrated safety in various clinical applications. The therapy targets angiogenesis, a critical process in tumor growth, and has shown potential in clinical studies. TSOI is also advancing its Phase III trial in COVID-19 related conditions.
Therapeutic Solutions International (TSOI) has announced the formation of a spin-off company, Res Nova Bio, Inc., focusing on developing the StemVacs-V anti-angiogenesis immunotherapy for breast cancer. This innovative therapy utilizes induced pluripotent stem cells (iPSCs) to create a therapeutic vaccine that targets tumor blood vessels, promoting immune response. The technology is expected to enhance treatment efficacy, capitalizing on past successes with similar therapies. TSOI positions itself as a hub of innovation, aiming for accelerated development through this strategic spin-off.
Therapeutic Solutions International (TSOI) successfully administered JadiCells™ to a treatment-resistant epilepsy patient, resulting in remarkable recovery after 35 years of debilitating seizures. The treatment was conducted under the Right to Try Act based on preclinical data supporting JadiCells™ efficacy over standard therapies. The Company has filed a patent for JadiCells™ use in epilepsy and is advancing Phase III trials for COVID-19. TSOI has also treated patients with Chronic Traumatic Encephalopathy under FDA IND protocols.
Therapeutic Solutions International (TSOI) announced the receipt of a 'Notice of Allowance' for its patent on 'Neuroprotection and Neuroregeneration by Pterostilbene'. This patent offers protection for brain cell stimulation and repair using components of QuadraMune®, now in commercial use. The company has two prior patents covering QuadraMune® for immune modulation related to cancer and COVID-19. CMO Dr. James Veltmeyer emphasized its potential in addressing COVID-19 neurological effects. TSOI is currently conducting a Phase III trial in COVID-19.
Therapeutic Solutions International (TSOI) announced promising findings regarding its universal donor stem cell therapy, indicating potential applications for treating Chronic Obstructive Pulmonary Disease (COPD) and Acute Respiratory Distress Syndrome (ARDS). Research showed that CD103 expressing dendritic cells can transfer protection against these conditions to naïve mice. The company is advancing a Phase III clinical trial for JadiCells targeting ARDS from COVID-19 and is in discussions with the FDA regarding a new drug application for COPD treatment.
Therapeutic Solutions International (TSOI) has entered a $10 million Common Stock Purchase Agreement with GHS Investments, LLC. This agreement is structured as a non-toxic equity investment, providing funds to accelerate TSOI's Phase III clinical trial of JadiCells for COVID-19 related lung injury. The trial's success could lead to treatments for issues like 'long COVID.' TSOI holds 66 patents and has various INDs targeting conditions including Chronic Traumatic Encephalopathy and Acute Respiratory Distress Syndrome, demonstrating a robust focus on regenerative medicine and immunotherapy.
FAQ
What is the current stock price of Therapeutic Solutions Intl (TSOI)?
What is the market cap of Therapeutic Solutions Intl (TSOI)?
